$5.63
+1.3%Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis
Chief Development Officer
Chief Operating Officer, Chief Financial Officer, Head of Corporate Development & Treasurer
Compensation
$809,946
President, Chief Executive Officer & Director
Compensation
$868,194
Senior Vice President of Clinical Development Operations
Senior Vice President of Finance & Operations
Senior Vice President of Investor Relations, Corporate Strategy & Communication
During the last 12 months, insiders have purchased $304K and sold $141K worth of IMA shares, resulting in $164K of net buying activity.
384.7K
384.00
0
0.00
+384
+$384
16.0K
95.84K
0
0.00
+96K
+$96K
0
0.00
0
0.00
+0
+$0
83.6K
208.19K
39.7K
140.77K
+67K
+$67K
Orbimed Advisors Llc
Director
$208K
Slattery Joseph P
Director
$96K
Bonita David P
Director
$384
Marango Jotin
Officer: Chief Financial Officer
$79K
Bonita David P
Director
$31K
Stampacchia Otello
Director
$31K
Positive insider sentiment with $164K net buying. Buying activity substantially exceeds selling, indicating insider confidence.
Strong buy/sell ratio. Buying is at least double the selling activity, suggesting robust insider confidence.
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
3 insider buyers and 3 sellers. Equal participation suggests mixed or neutral insider views.
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
IMA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 16, 2026 | 2026 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 07, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | September 25, 2023 | October 11, 2023 | 2023 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 09, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 27, 2022 | June 09, 2022 | 2022 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.